Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Gynecologic 1Breast 1

Conditions

Neoplasms 8Recurrence 5Neoplasm Metastasis 5Lymphoma 5Breast Neoplasms 5Sarcoma 4Endometrial Neoplasms 4Prostatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Glioblastoma 2Solid Tumors 1Solid Tumor 1Primary Myelofibrosis 1Osteosarcoma 1Myelodysplastic Syndromes 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Central Nervous System Neoplasms 1Bone Neoplasms 1

Interventions

Temozolomide 203Radiotherapy 118Bevacizumab 93Radiation 40Magnetic Resonance Spectroscopy 28Irinotecan 27Carmustine 25Surgical Procedures, Operative 24Lomustine 21Erlotinib Hydrochloride 19Chemotherapy, Adjuvant 18Carboplatin 17temsirolimus 13Drug Therapy 13O(6)-benzylguanine 12Nivolumab 12sargramostim 11Sirolimus 11Radiotherapy, Intensity-Modulated 11Radiotherapy, Conformal 11Sorafenib 10Radiosurgery 10Imatinib Mesylate 10Everolimus 10pembrolizumab 9motexafin gadolinium 9Vorinostat 9Thalidomide 8IL13-PE38 8Gefitinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Glioblastoma × ridaforolimus × Clear all
NCT01295632 2015-08-27

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Merck Sharp & Dohme LLC

Phase 1 Completed
65 enrolled
BreastCNSGynecologic

Breast Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT00087451 2015-08-19

Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 1 Completed
11 enrolled
CNSSarcoma

Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡